Kimberly Tang1, Jayhyun Seo1, Bruce C Tiu1,2, Thomas K Le3, Vartan Pahalyants1,2, Neel S Raval1,2,4, Pearl O Ugwu-Dike1, Leyre Zubiri5, Vivek Naranbhai5, Mary Carrington6,7,8, Alexander Gusev9, Kerry L Reynolds5, Nicole R LeBoeuf10, Maryam M Asgari1,2,11, Shawn G Kwatra3, Yevgeniy R Semenov1,2. 1. Massachusetts General Hospital, Department of Dermatology, Boston. 2. Harvard Medical School, Department of Dermatology, Boston, Massachusetts. 3. Johns Hopkins University, Department of Dermatology, Baltimore, Maryland. 4. Washington University School of Medicine, St Louis, Missouri. 5. Massachusetts General Hospital, Department of Medicine, Division of Oncology, Boston. 6. Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland. 7. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge. 8. Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. 9. Dana Farber Cancer Institute, Department of Medicine, Boston, Massachusetts. 10. Dana Farber Cancer Institute, Department of Dermatology, Boston, Massachusetts. 11. Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
Abstract
IMPORTANCE: Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our knowledge, little is known about the predictive value of these cutaneous eruptions and their subtypes regarding cancer survival. OBJECTIVE: To determine the association of developing cirAEs following treatment with anti-programmed cell death 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) therapy with patient survival. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the TriNetX Diamond Network, a database of health records and claims data from more than 200 million US and European patients, to conduct a population-level cohort analysis. The study included 7008 eligible patients who developed cirAEs after treatment with anti-PD-1 or anti-PD-L1 therapy for malignant neoplasms of digestive organs, bronchus or lung, melanoma of skin, and urinary tract who were identified through the TriNetX Diamond Network along with 7008 matched controls. EXPOSURES: Development of cirAEs within 6 months following anti-PD-1 or anti-PD-L1 therapy. MAIN OUTCOMES AND MEASURES: A 6-month analysis using a Cox proportional hazards model was performed to determine the association of cirAEs with overall survival after adjusting for demographic characteristics, cancer type, and cancer stage. RESULTS: A total of 7008 patients (3036 women [43.3%]; mean [SD] age, 68.2 [11.2] years) were matched to 7008 (3044 women [43.4%]; mean [SD] age, 68.3 [11.1] years) controls. Pruritus (hazard ratio [HR], 0.695; 95% CI, 0.602-0.803; P < .001), drug eruption (HR, 0.755; 95% CI, 0.635-0.897; P = .001), xerosis (HR, 0.626; 95% CI, 0.469-0.834; P = .001), nonspecific rashes (HR, 0.704; 95% CI, 0.634-0.781; P < .001), and appearance of any cirAE (HR, 0.778; 95% CI, 0.726-0.834; P < .001) were significantly protective of mortality using a Benjamini-Hochberg correction with a significance level of .05. Additionally, psoriasis (HR, 0.703; 95% CI, 0.497-0.994; P = .045) and lichen planus/lichenoid dermatitis (HR, 0.511; 95% CI, 0.279-0.939; P = .03) were significant. Eczematous dermatitis (HR, 0.612; 95% CI, 0.314-1.195), vitiligo (HR, 0.534; 95% CI, 0.254-1.123), bullous pemphigoid (HR, 0.524; 95% CI, 0.140-1.956), and Grover disease (HR, 0.468; 95% CI, 0.115-1.898) were all associated with strong protective clinical effects. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that the development of cirAEs is strongly associated with response to ICI therapy and patient survival.
IMPORTANCE: Despite the efficacy of immune checkpoint inhibitors (ICIs), cutaneous immune-related adverse events (cirAEs) occur in 20% to 40% of all treated patients. To our knowledge, little is known about the predictive value of these cutaneous eruptions and their subtypes regarding cancer survival. OBJECTIVE: To determine the association of developing cirAEs following treatment with anti-programmed cell death 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) therapy with patient survival. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from the TriNetX Diamond Network, a database of health records and claims data from more than 200 million US and European patients, to conduct a population-level cohort analysis. The study included 7008 eligible patients who developed cirAEs after treatment with anti-PD-1 or anti-PD-L1 therapy for malignant neoplasms of digestive organs, bronchus or lung, melanoma of skin, and urinary tract who were identified through the TriNetX Diamond Network along with 7008 matched controls. EXPOSURES: Development of cirAEs within 6 months following anti-PD-1 or anti-PD-L1 therapy. MAIN OUTCOMES AND MEASURES: A 6-month analysis using a Cox proportional hazards model was performed to determine the association of cirAEs with overall survival after adjusting for demographic characteristics, cancer type, and cancer stage. RESULTS: A total of 7008 patients (3036 women [43.3%]; mean [SD] age, 68.2 [11.2] years) were matched to 7008 (3044 women [43.4%]; mean [SD] age, 68.3 [11.1] years) controls. Pruritus (hazard ratio [HR], 0.695; 95% CI, 0.602-0.803; P < .001), drug eruption (HR, 0.755; 95% CI, 0.635-0.897; P = .001), xerosis (HR, 0.626; 95% CI, 0.469-0.834; P = .001), nonspecific rashes (HR, 0.704; 95% CI, 0.634-0.781; P < .001), and appearance of any cirAE (HR, 0.778; 95% CI, 0.726-0.834; P < .001) were significantly protective of mortality using a Benjamini-Hochberg correction with a significance level of .05. Additionally, psoriasis (HR, 0.703; 95% CI, 0.497-0.994; P = .045) and lichen planus/lichenoid dermatitis (HR, 0.511; 95% CI, 0.279-0.939; P = .03) were significant. Eczematous dermatitis (HR, 0.612; 95% CI, 0.314-1.195), vitiligo (HR, 0.534; 95% CI, 0.254-1.123), bullous pemphigoid (HR, 0.524; 95% CI, 0.140-1.956), and Grover disease (HR, 0.468; 95% CI, 0.115-1.898) were all associated with strong protective clinical effects. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that the development of cirAEs is strongly associated with response to ICI therapy and patient survival.
Authors: Leah L Thompson; Jordan T Said; Edward B Li; Jaewon Yoon; Nira A Krasnow; Gabriel E Molina; Nicole J Polyakov; Ruth K Foreman; Nicole R LeBoeuf; Steven T Chen Journal: Support Care Cancer Date: 2022-07-09 Impact factor: 3.359
Authors: Wenxin Chen; Guihong Wan; Nga Nguyen; Bonnie Leung; Jun Wen; Michael R Collier; Shawn G Kwatra; Yevgeniy R Semenov Journal: JAAD Int Date: 2022-08-18
Authors: Alyce M Kuo; Lukas Kraehenbuehl; Stephanie King; Donald Y M Leung; Elena Goleva; Andrea P Moy; Mario E Lacouture; Neil J Shah; David M Faleck Journal: Cancers (Basel) Date: 2022-06-17 Impact factor: 6.575
Authors: Kimberly Tang; Bruce C Tiu; Guihong Wan; Shijia Zhang; Nga Nguyen; Bonnie Leung; Alexander Gusev; Kerry L Reynolds; Shawn G Kwatra; Yevgeniy R Semenov Journal: J Natl Cancer Inst Date: 2022-08-08 Impact factor: 11.816
Authors: Megan L Baker; Yu Yamamoto; Mark A Perazella; Nazli Dizman; Anushree C Shirali; Navid Hafez; Jason Weinstein; Michael Simonov; Jeffrey M Testani; Harriet M Kluger; Lloyd G Cantley; Chirag R Parikh; F Perry Wilson; Dennis G Moledina Journal: J Immunother Cancer Date: 2022-03 Impact factor: 12.469